search
Back to results

Hepatic Glycogen and Fat Oxidation

Primary Purpose

Fatty Liver, Nonalcoholic, Meal Time, Fasting

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Overnight fasting duration
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Fatty Liver, Nonalcoholic

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Signed informed consent
  • Caucasian (people will be excluded when having a ≥50% racial African/Asian background)
  • Male or postmenopausal female
  • Aged 45-75 years at start of the study
  • Body mass index (BMI) 27 - 38 kg/m2
  • Stable dietary habits (no weight loss or gain >3kg in the past 3 months)
  • Sedentary lifestyle (not more than 2 hours of sports per week)
  • Liver fat ≥5% as determined by 1H-MRS

Exclusion Criteria:

  • Type 2 diabetes
  • Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)
  • Contra-indication for MRI (which can be found in appendix II)
  • Alcohol consumption of >2 servings per day
  • Regular smoking (>5 cigarettes per day)
  • No use of medication interfering with investigated study parameters (as determined by responsible physician)

Sites / Locations

  • Maastricht University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Short overnight fast

Long overnight fast

Arm Description

Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).

Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).

Outcomes

Primary Outcome Measures

Hepatic fat oxidation
measured as plasma BHB levels

Secondary Outcome Measures

De novo lipogenesis (DNL)
measured as percentage of palmitate in VLDL-TG originating from DNL

Full Information

First Posted
July 10, 2018
Last Updated
October 2, 2020
Sponsor
Maastricht University Medical Center
Collaborators
Unilever R&D
search

1. Study Identification

Unique Protocol Identification Number
NCT03593343
Brief Title
Hepatic Glycogen and Fat Oxidation
Official Title
The Effect of Modulating Hepatic Glycogen Content on Hepatic Fat Oxidation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
January 8, 2019 (Actual)
Primary Completion Date
January 8, 2020 (Actual)
Study Completion Date
January 13, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Unilever R&D

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Excessive fat in the liver is associated with impairments in metabolic health. Low levels of DNL and high levels of hepatic fat oxidation are considered to be protective. A decrease in glycogen stores has been causally linked to improved whole body fat oxidation. Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low hepatic glycogen stores. Next to hepatic fat oxidation, DNL may be influenced by hepatic glycogen stores. Some studies have shown that prolongation of fasting time lowers hepatic glycogen content. It is therefore hypothesized that prolonging fasting time will lower glycogen content and thereby increases fat oxidation and decreases DNL in the liver. To this end, hepatic fat oxidation (plasma marker beta-hydroxybutyrate), de novo lipogenesis, hepatic glycogen content and intrahepatic fat content, will be measured upon a short overnight fast and an extended overnight fast in 13 overweight/obese subjects with hepatic steatosis.
Detailed Description
Rationale: Excessive fat in the liver is associated with impairments in metabolic health. Hepatic lipid storage can originate from several metabolic pathways, including de novo lipogenesis (DNL). On the other hand, there are several metabolic pathways that can decrease hepatic fat storage, such as hepatic fat oxidation. Therefore, low levels of DNL and high levels of hepatic fat oxidation are considered to be protective. A decrease in glycogen stores has been causally linked to improved whole body fat oxidation. Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low hepatic glycogen stores. Furthermore, whole body glycogen levels were also linked to DNL and in situations with increased whole body glycogen levels in animal models rates of DNL were also high. Therefore, next to hepatic fat oxidation, DNL may be influenced by hepatic glycogen stores. Some studies have shown that prolongation of fasting time lowers hepatic glycogen content. It is therefore hypothesized that prolonging fasting time will lower glycogen content and thereby increases fat oxidation and decreases DNL in the liver. Objective: The primary objective of this study is to investigate to what extent hepatic fat oxidation can be stimulated by lowering hepatic glycogen content during a prolonged overnight fast. The secondary objective is to investigate whether reductions in hepatic glycogen content are also accompanied by a decrease in DNL. In addition, the metabolic response to a meal (metabolites related to energy metabolism and substrate oxidation) will be studied upon prolonged overnight fasting. Finally, it will be studied whether reducing hepatic glycogen content by prolonged overnight fasting during a few consecutive days lowers intrahepatic fat storage and changes hepatic fat composition. Study design: This is a randomized cross-over study. Study population: Thirteen healthy overweight/obese males and postmenopausal females, aged between 45-75 years and BMI between 27-38 kg/m2, with liver fat content ≥ 5% will participate in the study. To be able to include enough people with a liver fat content ≥5%, around 27 participants are expected to be screened for liver fat. When liver fat content is <5%, participants will not be included in the study after determination of liver fat content. Main study parameters/endpoints: The primary study outcome is hepatic fat oxidation measured as plasma beta-hydroxybutyrate (BHB) levels, which will be measured before and after one night adherence to the fasting protocols. The secondary study outcome is DNL as determined by stable isotope techniques and will also be measured after one night adherence to the fasting protocols. Other study outcomes include hepatic glycogen content, substrate oxidation and plasma metabolites related to energy metabolism (measured before and after one night adherence to the fasting protocols) and intrahepatic fat content and composition (measured after 6 days of adherence to the fasting protocols).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fatty Liver, Nonalcoholic, Meal Time, Fasting, Glycogen Depletion

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Short overnight fast
Arm Type
Experimental
Arm Description
Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
Arm Title
Long overnight fast
Arm Type
Experimental
Arm Description
Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
Intervention Type
Behavioral
Intervention Name(s)
Overnight fasting duration
Intervention Description
Subjects will adhere to overnight fasting protocol for 6 days
Primary Outcome Measure Information:
Title
Hepatic fat oxidation
Description
measured as plasma BHB levels
Time Frame
5 hours
Secondary Outcome Measure Information:
Title
De novo lipogenesis (DNL)
Description
measured as percentage of palmitate in VLDL-TG originating from DNL
Time Frame
20 hours
Other Pre-specified Outcome Measures:
Title
Hepatic glycogen content
Description
Measured with 13C-MRS
Time Frame
1 hour
Title
Intrahepatic fat accumulation and composition
Description
Measured with 1H-MRS
Time Frame
20 minutes
Title
Substrate oxidation
Description
measured with indirect calorimetry
Time Frame
30 minutes
Title
Plasma metabolites related to energy metabolism
Description
measured in plasma samples
Time Frame
5 hours
Title
Body composition
Description
fat mass/fat free mass measured with BodPod
Time Frame
5 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed informed consent Caucasian (people will be excluded when having a ≥50% racial African/Asian background) Male or postmenopausal female Aged 45-75 years at start of the study Body mass index (BMI) 27 - 38 kg/m2 Stable dietary habits (no weight loss or gain >3kg in the past 3 months) Sedentary lifestyle (not more than 2 hours of sports per week) Liver fat ≥5% as determined by 1H-MRS Exclusion Criteria: Type 2 diabetes Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) Contra-indication for MRI (which can be found in appendix II) Alcohol consumption of >2 servings per day Regular smoking (>5 cigarettes per day) No use of medication interfering with investigated study parameters (as determined by responsible physician)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vera Schrauwen-Hinderling, Dr
Organizational Affiliation
Maastricht University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Center
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 ER
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Hepatic Glycogen and Fat Oxidation

We'll reach out to this number within 24 hrs